drugset / Trial / NCT02183350
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes
RandomizedSingle-groupDouble-blindTreatment
Summary
The primary objective of the current study was to investigate the safety and tolerability of BI 1356 BS following administration of multiple rising oral doses of 1 mg, 2.5 mg, 5 mg, and 10 mg over 12 days in male patients with type 2 diabetes.
Timeline
- Start
- 2005-04
- Primary completion
- 2005-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linagliptin | Small molecule | 1 mg | Oral |
| Subject | Linagliptin | Small molecule | 2.5 mg | Oral |
| Subject | Linagliptin | Small molecule | 5 mg | Oral |
| Subject | Linagliptin | Small molecule | 10 mg | Oral |
| Subject | Linagliptin | Small molecule | 25 mg | Oral |